Clinical trial · Interventional
Image Guided Radiation Therapy For Prostate Cancer
Economic Evaluation of Image Guided Radiation Therapy For Prostate Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
During the 7 to 8 weeks of conformal radiotherapy for prostate carcinoma, the prostate has an intra-pelvic motion which is not detectable by the conventional portal imaging. This prostate motion may lead to a mistargeting, which possibly decreases the local control. On the other hand, the new 3D on board imaging (3D OBI) allows to localize the target but is expensive. The cost/effectiveness ratio is not well established, as well as the frequency of using such imaging during the course of radiation.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Prostate Cancer | Malignant Prostate Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Control position by 3DOBI before the fraction | Procedure | — | UNRESOLVED |
| Standard imaging | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Control position by 3DOBI daily
- interventionNames
- Procedure: Control position by 3DOBI before the fraction
- type
- ACTIVE_COMPARATOR
- label
- Standard imaging
- interventionNames
- Procedure: Standard imaging
Primary outcomes (2)
- measure
- Prostate position under the LINAC is checked by 3D OBI (mainly cone-beam imaging, CBI) performed before the fraction.
- measure
- To validate the optimal strategy of IGRT for prostate adenocarcinoma based on 2 and 5 year-disease free survival rates (events= biochemical failure or death).
Secondary outcomes (4)
Eligibility
Eligibility (as posted)
- Sex
- Male
Show eligibility criteria text
Inclusion Criteria: * prostate adenocarcinoma * intermediate / high risk group * N0 or N - * treatment by conformal radiotherapy (including or not IMRT), with or without androgen deprivation Exclusion Criteria: * pelvic irradiation * metal objects in the pelvis
References
Publications (1)
- RESULTPommier P, Morelle M, Perrier L, de Crevoisier R, Laplanche A, Dudouet P, Mahe MA, Chauvet B, Nguyen TD, Crehange G, Zawadi A, Chapet O, Latorzeff I, Bossi A, Beckendorf V, Touboul E, Muracciole X, Bachaud JM, Supiot S, Lagrange JL. [Prospective economic evaluation of image-guided radiation therapy for prostate cancer in the framework of the national programme for innovative and costly therapies assessment]. Cancer Radiother. 2012 Sep;16(5-6):444-51. doi: 10.1016/j.canrad.2012.07.178. Epub 2012 Aug 27. French. PMID 22951488